News

Article

In the Lab eNewsletter

Pharmaceutical Technology's In the Lab eNewsletter, March 2022
Volume17
Issue 3

FDA to Hold Public Symposium on Multi-Identification Biomarkers

FDA will hold a symposium discussing the identification of concepts and terminology for multi-component biomarkers from March 23–24, 2022.

FDA’s Center for Drug Evaluation and Research announced a new virtual workshop slated to happen on March 23–24, 2022. The public meeting, “Identification of Concepts and Terminology for Multi-Component Biomarkers,” will be held to discuss high-level terminology surrounding biomarkers.

According to an FDA press release, the goal of the symposium is to develop multi-component biomarker concepts and terminology, identify areas of conceptual language development, and discuss gaps in terminology for concepts and approaches as it relates to multi-component biomarkers.

The symposium will be held via live webcast for the public from 1:00–3:00 pm ET on both days. A full breakdown of the events schedule can be found here. The public will also gain access to additional pre-recorded talks three weeks prior to the live event, which FDA recommends viewing ahead of the event.

Source: FDA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
Understanding the Operational Impacts of the 15% US-EU Pharma Tariff Cap
Dave Miller, PhD, Chief Scientific Officer, AustinPx